Cancer Coverage
22 Tissues of Origin with up to 57 cancer sub-classes
Tissue of Origin | Cancer |
|---|---|
Central Nervous System | Brain Cancer |
Head and Neck | Nasal Cavity |
Head and Neck | Nasopharynx |
Head and Neck | Oral Cancer |
Head and Neck | Lip Cancer |
Head and Neck | Laryngeal Cancer |
Thyroid | Thyroid Cancer, Differentiated and Anaplastic |
Head and Neck | Cancer of the Hypopharygnx |
Head and Neck | Oropharynx (p16-) |
Head and Neck | Oropharynx, HPV-Mediated(p16+) |
Thyroid | Thyroid Cancer, Medullary |
Esophagus
| Esophageal Cancer |
Gastric | Esophagogastric Junction |
Gastric | Stomach Cancer, Adenocarcinoma |
Gastric | Stomach Cancer, Neuroendocrine |
Lung | Lung Cancer, Non-small Cell |
Lung | Lung Cancer, Small Cell |
Lung | Lung Cancer, Neuroendocrine |
Breast | Breast Cancer |
Liver | Liver Cancer |
Hepatobiliary System | Cholangiocarcinoma, Distal |
Hepatobiliary System | Cholangiocarcinoma, lntrahepatic |
Hepatobiliary System | Cholangiocarcinoma, Perihilar |
Hepatobiliary System | Gallbladder Cancer |
Pancreatic | Pancreas, Exocrine |
Pancreatic | Pancreas, Neuroendocrine |
Renal | Kidney Cancer |
Urothelial | Renal Pelvis |
Urothelial | Ureter |
Urothelial | Bladder, Urinary |
Urothelial | Urethra |
Cervical | Cervical Cancer |
Ovarian | Ovarian Cancer |
Ovarian | Fallopian Tube Cancer |
Endometrial | Corpus Uteri, Carcinoma and Carcinosarcoma |
Prostate | Prostate Cancer |
Colorectal | Small Intestine, Adenocarcinoma |
Colorectal | Small Intestine, Neuroendocrine |
Colorectal | Appendix, Carcinoma |
Colorectal | Colon cancer, Adenocarcinoma |
Colorectal | Colon cancer, Neuroendocrine |
Colorectal | Rectal Cancer, Adenocarcinoma |
Colorectal | Rectal Cancer, Neuroendocrine |
Colorectal | Anal Cancer |
Soft Tissue | Gastrointestinal Stromal Tumor |
Soft Tissue | Corpus Uteri, Sarcoma |
Soft Tissue | Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs |
Soft Tissue | Soft Tissue Sarcoma of the Head and Neck |
Soft Tissue | Soft Tissue Sarcoma of the Retroperitoneum |
Soft Tissue | Soft Tissue Sarcoma of the Trunk and Extremities |
Soft Tissue | Soft Tissue Sarcoma Unusual Histologies and Sites |
Melanoma | Melanoma of Skin |
Melanoma | Mucosal Melanoma |
Lymphatic | Lymphoma, Non-Hodgkin |
Lymphatic | Lymphoma, Hodgkin |
Hematopoetic | Leukemia |
Hematopoetic | Myeloma, Multiple Myeloma and Plasma Cell Disorders |
Sensitivity & Specificity
CanScan by GeneSeeq has a 79%, 87%, 92%, and 97% sensitivity for detecting Stage I, II, III, and IV cancers respectfully with 97.8% specificity upon independent validation.
​
Sensitivity is the % chance of picking up cancer with the screening test if the individual has cancer.
(True positive rate)
​
Specificity is the % chance of a negative test result if the individual does not have cancer.
(True negative rate)
​
​
GeneSeeq, American Association for Cancer Research Annual Meeting April 2024
Case-controlled Cohort Validation Study
CanScan was validated with case-controlled cohort analysis with both Internal and Independent testing for assessment of Sensitivity and Specificity.
GeneSeeq, American Association for Cancer Research Annual Meeting April 2024
Overall Performance
Stage
GeneSeeq, American Association for Cancer Research Annual Meeting April 2024
CanScan vs. "Conventional Screening"
A Prospective "Jinling" Cohort Study also in-progress for further clinical validation as well as comparison vs. conventional physical/clinical screening modalities.
In this case the "Physical Exam / Conventional Screening" represents existing "Best Practice" (which is considerably more aggressive than typical Canadian medical screening standards and practices in general): using screening methods including Liver Ultrasound/AFP for liver cancer, Kidney Ultrasound for Kidney cancer, Pap for cervical cancer, Breast ultrasound for breast cancer, PSA for prostate cancer, FIT for intestinal cancer, CT for lung cancer, ultrasound and CT for pancreatic cancer. These methods can additively yield a high false positive rate.
GeneSeeq, American Association for Cancer Research Annual Meeting April 2024
CanScan vs. "Conventional Screening"
Preliminary results in year 1, age 45-75
CanScanTP prospective cohort, SEER cancer incidence 1975-2021, CHINA multi-center observational study PMID: 34838194
Preliminary results from the prospective cohort study (N=3724, with recruitment target of 15,000) are promising for the Early Detection of Cancer with the majority (87.5%) of the cancers being found in Stage I and II compared to historical SEER data, and to "Conventional Screening" data.
Early Detection confers the opportunity for high rates of cancer remission and survival.
GeneSeeq, American Association for Cancer Research Annual Meeting April 2024
Ongoing Studies
The ongoing prospective study with CanScan to 2027 will also determine whether false positives are in fact non-cancerous cases, or whether CanScan is so sensitive that it would front-run conventional scanning technology by a number of years.
Hear the Clarion Call.
​
Give your self, your loved ones, and your employees the gift of foresight.